Inhibition of fibrinolysis

“Inhibition of fibrinolysis" is not a specific molecular target but rather describes a physiological process involving the suppression or downregulation of the body's ability to break down blood clots. Fibrinolysis is primarily mediated by the conversion of plasminogen to plasmin, which degrades fibrin clots. This process can be inhibited at several points by endogenous proteins such as α2-antiplasmin, plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI). These molecules act as key regulators that prevent excessive clot breakdown; elevated levels are linked to increased risk for venous thromboembolism and other cardiovascular diseases[2][3][4]. Therapeutically, drugs that inhibit these natural antifibrinolytic proteins—such as small molecule PAI-1 inhibitors or TAFI antagonists—are being explored to enhance clot dissolution in conditions like deep vein thrombosis or pulmonary embolism. Conversely, classic antifibrinolytic agents like tranexamic acid work by directly inhibiting the interaction between plasmin(ogen) and fibrin to reduce bleeding in hyperfibrinolytic states[6]. Because "inhibition of fibrinolysis" refers broadly to a mechanism rather than a discrete protein/receptor/enzyme entity, it should not be considered a canonical therapeutic target itself but instead represents an area where multiple molecular targets exist within the pathway.

Inhibition of plasminogen activation by blocking lysine binding sites on plasminogen/plasmin Direct inhibition of plasmin activity Inhibition of endogenous fibrinolysis inhibitors such as α2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI)